ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Approves Zokinvy for Hutchinson-Gilford Progeria Syndrome americanpharmaceuticalreview
December 08, 2020Eiger BioPharmaceuticals announced the U.S. Food and Drug Administration (FDA) has approved ZokinvyTM (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL). -
FDA approves first treatment for rare paediatric genetic diseases europeanpharmaceuticalreview
November 26, 2020Zokinvy (lonafarnib) capsules have been approved for the treatment of Hutchinson-Gilford progeria syndrome and certain progeroid laminopathies in patients over one year old.
Pharma Sources Insight January 2025
